¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"RNA plasmid"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • RNA splicing
    RNA½ºÇöóÀ̽Ì, ¸®º¸ÇÙ»êÀß¶óÀÌÀ½
  • RNA virus
    RNA¹ÙÀÌ·¯½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • RNA
    (¢¡ribonucleic acid) ¸®º¸ÇÙ»ê, ¾Ë¿£¿¡ÀÌ
  • ribosomal RNA
    ¸®º¸¼Ø¾Ë¿£¿¡ÀÌ
  • RNA splicing
    ¾Ë¿£¿¡ÀÌÂ¥±é±â, ¸®º¸ÇÙ»êÂ¥Áý±â
  • RNA virus
    ¾Ë¿£¿¡À̹ÙÀÌ·¯½º
  • transfer RNA
    Àü´Þ¾Ë¿£¿¡ÀÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasmid, nonconjugative
    ºñÁ¢ÇÕ¼º Çö󽺹̵å
  • plasmid, resistance (R)
    ³»¼ºÇö󽺹̵å, RÇö󽺹̵å
  • plasmid, transferable
    Àü´Þ¼º Çö󽺹̵å
  • plasmid, transmissible
    Àü´Þ¼º Çö󽺹̵å
  • plasmid, virulence
    º´¿ø¼º Çö󽺹̵å, ¹ßº´´É Çö󽺹̵å
  • DNA polymerase, RNA dependent
    RNA- ÀÇÁ¸ DNA ÁßÇÕÈ¿¼Ò
  • DNA polymerase, RNA-dependent
    RNA-ÀÇÁ¸ DNA ÁßÇÕÈ¿¼Ò
  • DNA-RNA hybridization
    DNA-RNA ¦Áö¿ì±â, DNA-RNA ºÎÇÕ°Ë»ç¹ý(ݬùê~)
  • DNA-dependent RNA polymerase
    DNA-ÀÇÁ¸ DNA ÁßÇÕÈ¿¼Ò
  • DNA-dependent RNA polymerase
    DNA-ÀÇÁ¸ RNA ÁßÇÕÈ¿¼Ò
  • RNA =>ribonucleic acid
    ¸®º¸ÇÙ»ê
  • RNA editing
    RNA ±³Á¤
  • RNA polymerase
    RNA ÁßÇÕÈ¿¼Ò
  • RNA polymerase I
    RNA ÁßÇÕÈ¿¼Ò I
  • RNA recombination
    RNA Àç°áÇÕ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ribonucleic acid =RNA
    ¸®º¸ÇÙ»ê (¡­ú·ß«).
  • ribosomal RNA
    ¸®º¸¼Ø¸®º¸ÇÙ»ê(¡­ú·ß«).
  • rna oncogenic virus
    RNA(¸®º¸ÇÙ»ê)¹ß¾Ï¼º ¹ÙÀÌ·¯½º(Û¡äßàõ¡­)
  • subgenomic RNA
    ¾ÆÁö³ð RNA
  • subgenomic m-RNA
    ¾ÆÁö³ð mRNA
  • transfer RNA
    ÀüÀÌ RNA
  • bacterial plasmid
    ¼¼±ÕÇö󽺹̵å
  • chimeric plasmid
    Çö󽺹̵å Ű¸Þ¶ó
  • colicin plasmid
    Äݸ®½Å»ý¼º Çö󽺹̵å, ColÇö󽺹̵å
  • conjugative plasmid
    Á¢ÇÕ¼º Çö󽺹̵å
  • cryptic plasmid
    ÀáÀûÇö󽺹̵å
  • curing, plasmid
    Çö󽺹̵å Á¦°Å
  • drug resistance plasmid
    ¾àÁ¦³»¼º Çö󽺹̵å
  • hybrid plasmid
    ÇÏÀ̺긮µåÇö󽺹̵å
  • incompatibility group, plasmid
    ÇÃ¶ó½º¹Ìµå ºñÀûÇÕ±º
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • plasmid curing
    Çö󽺹̵å Á¦°Å(ð¶ËÛ)
  • plasmid donation
    Çö󽺹̵å Á¦°ø(ð«Íê)
  • plasmid engineering
    ÇÃ¶ó½º¹Ìµå °øÇÐ(ÍïùÊ)
  • plasmid fusion
    Çö󽺹̵å À¶ÇÕ(ë×ùê)
  • plasmid incompatibi;ity
    ÇÃ¶ó½º¹Ìµå ºÒÇùÈ­(ÝÕúðûú)
  • plasmid transfer
    Çö󽺹̵å Àü´Þ(îîÓ¹)
  • relaxed plasmid
    ÀÌ¿Ï(ì¬èÐ) Çö󽺹̵å
  • R plasmid
    R Çö󽺹̵å
  • self-transmissible plasmid
    ÀÚ±âÀüÆÄ¼º(í»Ðùîî÷êàõ) Çö󽺹̵å
  • sex plasmid
    ¼º(àõ)Çö󽺹̵å
  • single-copy plasmid
    ´Ü(Ó¤)Ä«ÇÇ Çö󽺹̵å
  • stringent plasmid
    ¾ö°Ý(åñÌ«)Çö󽺹̵å
  • Ti plasmid
    Ti Çö󽺹̵å
  • transmissible plasmid
    ÀüÆÄ¼º(ï®÷îàõ) Çö󽺹̵å
  • acceptor RNA
    ¼ö¿ë(â¥é»)RNA
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
poly-IC, poly-I:C copolymer of polyinosinic and polycytidylic acids; synthetic RNA polymer
RNA radionuclide angiography; Registered Nurse Anesthetist; ribonucleic acid; rough, noncapsulated, avir...
U-RNA uridylic acid ribonucleic acid
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
I-RNA Immune RNA
poly(A)+ RNA Polyadenylated RNA
RDRP RNA dependent RNA polymerase
sat RNA satellite RNA
n-RNA nuclear RNA
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
acceptor RNA rNA
antisense RNA <molecular biology> A complementary RNA sequence that binds to (and thus blocks the transcription of) a naturally-occuring (sense) messenger RNA molecule.
These proteins can be used to selectively turn off production of certain proteins or block viral genetic instructions, by marking them for destruction by cellular enzymes, in order to prevent the building of new virus or the infection of new cells.
(09 Oct 1997)
bacteriophage T3 RNA polymerase <enzyme> Used for the rapid generation of strand-specific RNA molecules that can be used for the identification of genes in hybridization experiments
Registry number: EC 2.7.7.-
Synonym: t3 RNA polymerase
(26 Jun 1999)
cap II RNA(nucleoside-2'-)methyltransferase <enzyme> Converts cap i-terminated mRNA to cap II-terminated mRNA
Registry number: EC 2.1.1.-
Synonym: cap II methylase
(26 Jun 1999)
cap I RNA (nucleoside-2'-)methyltransferase <enzyme> Converts cap 0-terminated mRNA to cap i-terminated mRNA
Registry number: EC 2.1.1.-
Synonym: cap I methylase
(26 Jun 1999)
p68 RNA helicase <enzyme> An RNA helicase isolated from uv-induced tumours in mice; amino acid sequence has been determined
Registry number: EC 2.7.7.-
Synonym: dead box helicase p68
(26 Jun 1999)
masked messenger RNA <molecular biology> Long lived and stable mRNA found originally in the oocytes of echinoderms and constituting a store of maternal information for protein synthesis that is unmasked (derepressed) during the early stages of morphogenesis.
In these early stages the rate of cell division is so rapid that transcription from the embryonic genome cannot occur. Undoubtedly not restricted to oocytes and the term can be applied to any mRNA which is present in inactive form.
(18 Nov 1997)
ribosomal RNA <molecular biology> A nucleic acid found in all living cells. Plays a role in transferring information from DNA to the protein-forming system of the cell.
(16 Dec 1997)
messenger-like RNA An ill-defined form of RNA, of high molecular weight, that never leaves the nucleus and is thought to be the precursor of messenger RNA.
(05 Mar 2000)
messenger RNA <molecular biology> Single stranded RNA molecule that specifies the amino acid sequence of one or more polypeptide chains. This information is translated during protein synthesis when ribosomes bind to the mRNA.
In prokaryotes, mRNA is normally formed by splicing a large primary transcript from a DNA sequence and protein synthesis starts while the mRNA is still being synthesised. Prokaryote mRNAs are usually very short lived (average t 1/2 is 5mins.).
In contrast, in eukaryotes the primary transcripts (HnRNA) are synthesised in the nucleus and they are extensively processed to give the mRNA that is exported to the cytoplasm where protein synthesis takes place.
This processing includes the addition of a 5' 5' linked 7 methyl guanylate cap at the 5' end and a sequence of adenylate groups at the 3' end, the poly A tail, as well as the removal of any introns and the splicing together of exons, only 10% of HnRNA leaves the nucleus.
Eukaryote mRNAs are comparatively long lived with a half life ranging from 30minutes to 24 hours.
(27 Jun 1999)
GTP-RNA guanylyltransferase <enzyme> Catalyses addition of GMP residue to 3'-ends of oligonucleotide primers
Registry number: EC 2.7.7.-
Synonym: terminal guanylyltransferase
(26 Jun 1999)
RNA <molecular biology> A nucleic acid found in all living cells. Plays a role in transferring information from DNA to the protein-forming system of the cell.
(16 Dec 1997)
RNA 2'-O-methyltransferase <enzyme> Methylates 2'-hydroxyl group of ribose moieties of ribosomal RNA; highest activity poly (c) is a synthetic substrate
Registry number: EC 2.1.1.-
Synonym: nucleolar 2'-o-methyltransferase
(26 Jun 1999)
RNA 3'-terminal phosphate cyclase <enzyme> ATP dependent; forms 2',3' terminal cyclic phosphate on RNA which is then the substrate for RNA ligase of hela cells
Registry number: EC 6.5.-
Synonym: RNA tph cyclase
(26 Jun 1999)
RNA, antisense An RNA molecule which, by binding to a complementary sequence in either RNA or DNA, inhibits the function and/or completion of synthesis of the latter molecule. It is involved in various regulatory systems in vivo. Artificial antisense rnas have been used to inhibit translation of specific mRNA molecules both in living cells (eukaryotic and bacterial) and in cell-free systems.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á